3 results
In the present study the effects of the colonic administration of butyrate on portal, hepatic, mesenteric venous and arterial SCFA concentrations will be studied in patients undergoing major upper abdominal surgery. The aim is to clarify the…
To assess the number of patients in remission, 12 months after dose adjustment of IFX from 5mg/kg to 3 mg/kg. Secondary objectives include: number of relapses, defined by increase of fecal calprotectin and/or CRP and clinical activity, subsequently…
To evaluate the tofacitinib and infliximab treatment-induced changes in plasma lipids and lipoproteins and to provide insight in the underlying mechanism in relation to the inflammatory status in patients with active UC.